All News

Immunotherapies continue to be studied and approved across multiple tumor types, among them, malignancies of the central nervous system.

The approval was based on data from the phase 3 ELOQUENT-2 trial, in which adding Empliciti to standard Revlimid (lenalidomide)/dexamethasone reduced the risk of disease progression by 30 percent.

The treatment paradigm for patients with triple-negative breast cancer is set to undergo a dramatic transformation, as standard chemotherapeutic approaches are perfected and novel antibody-drug conjugates are developed.

Every cancer conference is a chance for me to learn.

My mother chose to live by asking for help, and so can I.

The approval was based findings from the phase 3 SQUIRE trial.

The approval was based on a substantial improvement in overall survival (OS) in a phase 3 study.

It's always something, isn't it?

As a patient advocate for those with hereditary cancer syndromes, I receive countless calls every week from women asking me about prophylactic procedures.

Pharmacies hopefully aim to help all their patients feel better, yet a common practice is making some patients feel worse. You can do something about it.

Though clinical work is ongoing and early, researchers are already considering how to manage potentially fatal neurotoxicities in patients treated with chimeric antigen receptor (CAR) T-cell therapy.

The approval was based on an extension in overall survival (OS) in the CheckMate-025 trial.

The approval was based on an extension in overall survival from two phase 3 studies.

Enjoy the holidays without the guilt.

A breast cancer and melanoma survivor shares what Thanksgiving helped teach her.

It was a night filled with inspiration, shared purpose and hope, as four heroes who have given selflessly in their efforts to improve the lives of people impacted by glioblastoma were honored at the 1st Annual Glioblastoma Multiforme (GBM) Heroes Awards.

The FDA has approved the oral medication Ninlaro in combination with Revlimid and dexamethasone for patients with multiple myeloma.

Immune checkpoint inhibitors have demonstrated encouraging results for patients with small cell lung cancer (SCLC) and mesothelioma, two aggressive thoracic malignancies with few options.

A phase 3 study exploring Zydelig in combination with Treanda and Rituxan for patients with previously treated CLL has been stopped early following a positive interim analysis.

Adding the MEK inhibitor Mekinist to the BRAF inhibitor Tafinlar significantly improves long-term outcomes while lowering certain adverse events associated with either agent alone.

Parenting a child with a life-threatening illness like cancer is associated with unique demands and simultaneously raising healthy siblings can add another layer of complexity.

In a recent survey, 48 percent of insured patients with cancer indicated that they never wanted to discuss the topic of out-of-pocket treatment costs.

The dramatic and often practice-changing findings demonstrated by trials of immunotherapies in melanoma and lung cancer may soon be reflected in the treatment of bladder cancer.

As part of this program, the FDA plans to take action on the drug's application within six months instead of the standard 10 months under regular review.

The holidays are so intertwined with the notion of stress that if you Google the term "holiday stress," you'll get 24,500,000 results.

Nexavar and Lenvima have significantly altered the treatment paradigm for patients with advanced RAI-refractory differentiated thyroid cancer, with combination strategies hoping to further build upon this success.

Neoadjuvant chemotherapy is increasingly used in advanced ovarian cancer, even though it has not been shown to improve survival versus primary cytoreduction.

Two-time cancer survivor discusses her fatigue and possible answers for it.

The approval was based on data from two open-label clinical trials.

To gain insight into the recent flurry of FDA approvals in melanoma, CURE spoke with Tim Turnham, the executive director of the Melanoma Research Foundation.